TRAF3IP2 and diabetic foot: To date, the αCT1 peptide has shown promising results as a therapy for a variety of conditions at the pre-clinical and clinical levels, including cardiac disease, retinal injury, and wound healing; recently reporting successful phase II clinical trial data on the use of αCT1 for the treatment of venous leg ulcers and diabetic foot ulcers [48,53,167,168,169,170,171].